dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

Dexmethylphenidate

Focalin, d-MPH, Attenade

Psychoactive Class

Stimulant

Chemical Class

Phenidate

Dexmethylphenidate is the more pharmacologically active enantiomer of methylphenidate, classified as a central nervous system stimulant and norepinephrine-dopamine reuptake inhibitor.¹ Approved for medical use in the United States in 2001 and sold under the brand name Focalin, it is primarily prescribed for the treatment of ADHD.citation needed It is approximately twice as potent as racemic methylphenidate² and is reported to produce cleaner stimulant effects with fewer side effects. It is considered habit-forming.¹

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~10 mg

Light10-20 mg

Moderate20-30 mg

Strong30-40 mg

Heavy40+ mg

Bioavailability

23%

Duration

Onset30-60 minutes

Come Up20-45 minutes

Peak1-2 hours

Offset45-60 minutes

After Effects2-6 hours

Total3-5 hours

Half-life

2.2-5.7 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

The experience is that of a focused, functional psychostimulant rather than a recreational euphoriant. As the more pharmacologically active dextrorotary isomer of methylphenidate, dexmethylphenidate is roughly twice as potent by weight and is often described as producing a cleaner stimulation with fewer side effects than the racemic compound. At therapeutic doses the effects center on improved concentration, resistance to distraction, and behavioral control, with wakefulness and appetite suppression as prominent physical accompaniments. Euphoria, hallucinations, and confusion are largely confined to heavy doses and overdose, where central nervous system overstimulation dominates the experience.

Physical

The body load is that of a classic central nervous system stimulant: wakefulness, appetite loss, dry mouth, and elevated heart rate and blood pressure. Restlessness, headache, dizziness, and nausea occur in a subset of users, with sweating, tremor, and hyperthermia emerging at excessive doses.

Cardiovascular

Increased blood pressure

Stimulation

Uncomfortable

Dry mouth NauseaHeadaches Dizziness

Cognitive

The headspace is clear and task-oriented, characterized by enhanced concentration and reduced distractibility. Anxiety, nervousness, irritability, and agitation are common accompaniments, and heavy use carries a risk of paranoia, mania, or psychotic symptoms in susceptible individuals.

Emotional

Irritability

Enhancements

Wakefulness

Visual

Visual effects are limited to side effects such as blurred vision at normal doses; hallucinations are very rare and associated primarily with overdose.

Pharmacology

Pharmacodynamics

Dexmethylphenidate is the more pharmacologically active d-threo enantiomer of methylphenidate, functioning primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI).citation needed It blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), increasing catecholaminergic neurotransmission particularly in the striatum and mesolimbic system. Beyond competitive reuptake inhibition, dexmethylphenidate also functions as a negative allosteric modulator of DAT, stabilizing the transporter in an outward-facing conformation that promotes dopamine efflux from the presynaptic terminal into the synaptic cleft. It additionally exhibits weak affinity for the serotonin transporter (SERT) and weak partial agonism at 5-HT1A receptors.

Pharmacokinetics

Dexmethylphenidate is well absorbed orally (approximately 90%), but extensive hepatic first-pass metabolism reduces its oral bioavailability to roughly 23%.citation needed It is metabolized primarily by carboxylesterase 1A1 (CES1A1) to the inactive metabolite ritalinic acid, with minor pathways producing 6-oxo-methylphenidate and p-hydroxy-methylphenidate. Beyond CES1, evidence indicates substantial contributions from CYP2B6, CYP2E1, and CYP3A4 to overall metabolic clearance. Protein binding is low at approximately 12-16%, and roughly 90% of a dose is eliminated renally within 48 hours. The mean terminal elimination half-life has been reported variably across studies, ranging from approximately 2.2 hours to nearly 6 hours.

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check

TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance

Tolerance may develop with continued use of stimulants such as methylphenidate, though the excerpts do not specify a timeframe.⁴

Harm Potential

Addiction & Dependence

Psychological

Moderate

Moderate liability among addictive drugs; psychological dependence may occur, particularly when used at high doses or in non-medical contexts. At therapeutic doses prescribed for ADHD treatment, methylphenidate lacks the capacity to cause addiction as it does not sufficiently activate the reward system. Repeated high-dose administration can induce expression of ΔFosB in the nucleus accumbens, a biomolecular mechanism associated with drug addiction.

Physical

Low

Displays dependence liability similar to amphetamine. Physical dependence is not prominently described in the literature compared to psychological dependence, consistent with the stimulant class profile.

Toxicity

Cardiovascular

Sudden death has been reported in patients with pre-existing cardiac structural abnormalities,⁵ arrhythmias, coronary disease, or other cardiac conditions; however, FDA-commissioned studies in 2011 found no association between serious cardiovascular events and medical use of methylphenidate in otherwise healthy individuals.

Hepatic

Liver toxicity is extremely rare with therapeutic use; animal studies in B6C3F1 mice, which are particularly sensitive to hepatic tumors, showed hepatoblastoma development at twice the maximum recommended human dose.

Ophthalmologic

Can increase intraocular pressurecitation needed due to pupil dilation, which may cause further optic nerve damage in patients with pre-existing glaucoma; occasional users without glaucoma face minimal risk.

Growth and Development

Prolonged treatment in children may cause mild reductions in height, estimated at approximately 1 cm or less per year during the first three years, with a cumulative decrease of about 3 cm over 10 years of use.

Carcinogenicity

Possible

Considered unlikely to be carcinogenic based on available evidence. Not mutagenic but weakly clastogenic in Chinese Hamster Ovary cells. Hepatoblastomas observed only in B6C3F1 mice, a strain particularly sensitive to hepatic tumor development, at doses twice the maximum recommended human dose.

Evidence Basis

Human EpidemiologicalNone

Animal Models

Limited

(mouse)

In Vitro

non-genotoxic

mutagenicity assays and Chinese Hamster Ovary cell clastogenicity testing

Psychosis Risk

Can worsen psychosis in individuals who are already psychotic, and in very rare cases has been associated with the emergence of new psychotic symptoms.citation needed Should be used with extreme caution in people with bipolar disorder due to potential induction of mania or hypomania. Visual hallucinations are very rarely reported.

Seizure Risk

Seizures are listed among serious but uncommon side effects. Convulsions may occur in severe overdose situations involving sympathomimetic toxidrome.⁵

History & Culture

Dexmethylphenidate is the dextrorotatory enantiomer of methylphenidate⁵, isolated and developed as a separate pharmaceutical product. It received approval for medical use in the United States in 2001⁵ and was subsequently…

Legality

By Country

Prescription1

United StatesPrescription only

References

Citations

Article Status

Step 1 · Automated synthesis
An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest 30 Aug

Times are UTCNewest first

30 August 2026

23:03
Lyrea · Changed a word in Dosage & Duration › Routes 1 › Stages › Total duration
23:03
Lyrea · Changed a word in Dosage & Duration › Routes 1 › Stages › After effects
23:03
Lyrea · Reworded 2 words in Dosage & Duration › Routes 1 › Stages › Offset
23:03
Lyrea · Reworded 2 words in Dosage & Duration › Routes 1 › Stages › Peak
23:03
Lyrea · Reworded 2 words in Dosage & Duration › Routes 1 › Stages › Peak
23:02
Lyrea · Changed a word in Dosage & Duration › Routes 1 › Stages › Come up
23:02
Lyrea · Changed a word in Dosage & Duration › Routes 1 › Stages › Onset
22:59
Lyrea · Added a citation in Pharmacology › Pharmacokinetics

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Dexmethylphenidate article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.